제약협회 공정경쟁규약의 개정필요성과 개선방안

Although the Korean Pharmaceutical Manufacturers Association's Promotion Code has actual binding power over the medical community, the pharmaceutical industry and the medical community currently have cast their doubtful and skeptical eyes on the Code's legitimacy and efficacy. It is undeniable that the Code has many intrinsic problems such as the absence of provision allowing physicians' consultations and lectures, the unrealistic case number and compensation allowed in post marketing surveillance and the ambiguity of clinical trials provision. It's notable that such problems are not found in the United States or Japanese pharmaceutical promotion codes. In this context, it is highly needed to revise the provisions of the Code containing such problems in order to enhance the legitimacy of the Code.